Meeting
2022 ASCO Annual Meeting
Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma (DLBCL) in first relapse.
Authors
Amar Harry Kelkar
Dana-Farber Cancer Institute, Boston, MA
Amar Harry Kelkar , Edward Robert Scheffer Cliff , Caron Alyce Jacobson , Gregory A. Abel , Robert Redd , Stijntje Dijk , Eline Krijkamp , M. G. Myriam Hunink , Corey S. Cutler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7537)
DOI
10.1200/JCO.2022.40.16_suppl.7537
Abstract #
7537
Poster Bd #
190
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2022 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
First Author: Nancy L. Bartlett
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).
First Author: Nancy L. Bartlett